Business Context and Reporting Period
This Form 8-K was filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on December 14, 2021. The registrant is a Delaware corporation with its principal executive offices in New York, NY. The filing reports the entry into a new material definitive agreement and the termination of a prior agreement regarding the sale of common stock.
Key Financial Metrics and Transaction Details
This filing does not report revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed relates to a capital raising mechanism:
- Offering Size: Up to $50.0 million in aggregate offering price of common stock.
- Commission: The sales agent, SVB Leerink LLC, will receive a commission of 3.0% of gross sales proceeds.
- Stock Class: Common stock, $0.0001 par value (Trading Symbol: EYEN).
Material Changes Versus Prior Period
The filing details a specific change in the company's capital raising structure:
- New Agreement: Eyenovia entered into a new Sales Agreement with SVB Leerink LLC on December 14, 2021, allowing for "at the market" offerings.
- Termination: The prior Sales Agreement dated May 14, 2021, between Eyenovia and SVB Leerink was terminated effective upon the effectiveness of the new Registration Statement.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The company is not obligated to make any sales under the new agreement. Sales will be made at the company's sole discretion based on market conditions and instructions provided to the sales agent. The offering will terminate upon the sale of all shares or earlier termination of the agreement.
Risks and Contingencies: The filing notes that the sale of securities is subject to the terms of the Registration Statement on Form S-3. The report explicitly states it does not constitute an offer to sell securities in any state where such an offer would be unlawful prior to registration.
Important Facts for Investor Verification
- Verify the exact number of shares sold and proceeds raised under the new $50.0 million Sales Agreement in subsequent filings.
- Confirm the impact of the 3.0% commission on net proceeds from any future stock sales.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions not detailed in this summary.
- Note that this filing contains no operational financial results (revenue, earnings) for the period.